Iniciar sesión
Registrarse
Restablecer contraseña
Publicar y Distribuir
Soluciones de Publicación
Soluciones de Distribución
Temas
Arquitectura y diseño
Artes
Ciencias Sociales
Ciencias de la Información y Bibliotecas, Estudios del Libro
Ciencias de la vida
Ciencias de los materiales
Deporte y tiempo libre
Estudios clásicos y del Cercano Oriente antiguo
Estudios culturales
Estudios judíos
Farmacia
Filosofía
Física
Geociencias
Historia
Informática
Ingeniería
Interés general
Ley
Lingüística y semiótica
Literatura
Matemáticas
Medicina
Música
Negocios y Economía
Química
Química industrial
Teología y religión
Publicaciones
Revistas
Libros
Actas
Editoriales
Blog
Contacto
Buscar
EUR
USD
GBP
Español
English
Deutsch
Polski
Español
Français
Italiano
Carrito
Home
Revistas
Slovenian Journal of Public Health
Volumen 60 (2021): Edición 4 (December 2021)
Acceso abierto
Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients
Blaž Matija Geršak
Blaž Matija Geršak
,
Andreja Kukec
Andreja Kukec
,
Henning Steen
Henning Steen
,
Moritz Montenbruck
Moritz Montenbruck
,
Maja Šoštarič
Maja Šoštarič
,
Arne Kristian Schwarz
Arne Kristian Schwarz
,
Sebastian Esch
Sebastian Esch
,
Sebastian Kelle
Sebastian Kelle
,
Sorin Giusca
Sorin Giusca
,
Grigorios Korosoglou
Grigorios Korosoglou
,
Pia Wülfing
Pia Wülfing
,
Susan Dent
Susan Dent
y
Daniel Lenihan
Daniel Lenihan
| 20 oct 2021
Slovenian Journal of Public Health
Volumen 60 (2021): Edición 4 (December 2021)
Acerca de este artículo
Artículo anterior
Artículo siguiente
Resumen
Artículo
Figuras y tablas
Referencias
Autores
Artículos en este número
Vista previa
PDF
Cite
Compartir
Article Category:
Original scientific article
Publicado en línea:
20 oct 2021
Páginas:
199 - 209
Recibido:
09 mar 2021
Aceptado:
31 mar 2021
DOI:
https://doi.org/10.2478/sjph-2021-0028
Palabras clave
antineoplastic agents
,
cardiotoxicity
,
ventricular function – left
,
ventricular function – right
,
quality of life
,
magnetic resonance imaging
,
cine
,
echocardiography
,
lymphoma
,
Hodgkin disease
,
breast neoplasms
© 2021 National Institute of Public Health, Slovenia, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
EQ-5D questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 2
EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 3
EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 4
SF-36 physical component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 5
SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 6
SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 7
SF-36 mental component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 8
SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 9
SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Vista previa